Search
MVA-BN-brachyury-TRICOM vaccine
go.drugbank.com/drugs/DB17424Investigationalof T-cell co-stimulatory molecules (TRICOM), which is comprised of the three human immune-enhancing co-stimulatory molecules B7-1, ICAM-1 and LFA-3. … [L44513] MVA-BN-brachyury-TRICOM vaccine is administered as a priming vaccine, followed by the administration of the fowlpox virus(FPV)‐Brachyury booster vaccine.
Bevirimat
go.drugbank.com/drugs/DB06581InvestigationalBevirimat is derived from a betulinic acid-like compound, first isolated from <i>Syzygium claviflorum</i>, a Chinese herb. … Bevirimat, also known as PA-457 or YK-FH312, is investigated in clinical trials for treating HIV infection. Bevirimat is a solid.
Somatostatin
go.drugbank.com/drugs/DB09099ApprovedInvestigationalWithdrawn[DB00104] is a long-acting analogue of somatostatin that inhibits the release of a number of hormones, and is clinically used to relieve symptoms of uncommon gastroenteropancreatic endocrine tumours, as … Somatostatin is initially secreted as a 116 amino acid precursor, preprosomatostatin, which undergoes endoproteolytic cleavage to prosomastatin.
Categories: P-glycoprotein substrates, Cytochrome P-450 CYP3A InhibitorsProducts: SOMATEX 3 MG I.V. İNFÜZYONLUK ÇÖZELTİ HAZIRLAMAK İÇİN TOZ VE ÇÖZÜCÜ, 1 FLAKON + 1 ÇÖZÜCÜ AMPUL, SOMATOSAN 3 MG IV INFUZYON ICIN 1 AMPULEliapixant
go.drugbank.com/drugs/DB21465InvestigationalEliapixant has a monoisotopic molecular weight of 478.13 Da. … Eliapixant is a small molecule drug. The usage of the INN stem '-pixant' in the name indicates that Eliapixant is a purinoreceptor (P2X) antagonist.
ADH-1
go.drugbank.com/drugs/DB05485InvestigationalADH-1 may have utility in a wide variety of cancers as N-cadherin is overexpressed in a variety of tumors. … Poorly differentiated, highly invasive carcinomas are characterized by over-expression of N-cadherin (as opposed to E-cadherin).
Synonyms: l-cysteinamide, n-acetyl-l-cysteinyl-l-histidyl-l-alanyl-l-valyl-, cyclic (1-5)-disulfide, Cys-His-Ala-Val-CysBetibeglogene autotemcel
go.drugbank.com/drugs/DB16900ApprovedInvestigational[L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770] Allogeneic hematopoietic-cell transplantation would be a therapeutic option in patients with β-thalassemia; however, this process is reserved for young children with an HLA-identical sibling
Synonyms: Autologous CD34+ cells encoding βA-T87Q-Globin geneEtesevimab
go.drugbank.com/drugs/DB15897InvestigationalEtesevimab (LY-CoV016, also known as JS016) is a fully human and recombinant monoclonal antibody that targets the SARS-CoV-2 surface spike protein receptor binding domain.
Albinterferon Alfa-2B
go.drugbank.com/drugs/DB05396InvestigationalRecombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B, and a broad range of cancers. … Human Genome Sciences is developing Albuferon as a potential treatment for chronic hepatitis C.
Categories: Interferon Type I, Cytochrome P-450 CYP1A2 InhibitorsSarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationalSubsequently, while a number of first line tetracycline therapies like doxycycline and minocycline do exist for treating acne vulgaris, sarecycline presents a new and innovative therapy choice because … it exhibits the necessary antibacterial activity against relevant pathogens that cause acne vulgaris but also possesses a low propensity for resistance development in such pathogens and a narrower, more
Categories: P-glycoprotein inhibitorsEfonidipine
go.drugbank.com/drugs/DB09235InvestigationalThe drug has been shown to block T-type in addition to L-type calcium channels [A7844, A32001]. It has also been studied in atherosclerosis and acute renal failure [A32001]. … Efonidipine is a calcium channel blocker of the _dihydropyridine class_, commercialized by Shionogi & Co. (Japan). Initially, it was marketed in 1995 under the trade name, _Landel_.
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-Ring